Author

S. Grund-Groeschke

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

F. Aberger· 4 shared A. Risch· 2 shared D. P. Elmer· 2 shared R. Moriggl· 2 shared A. Carracedo· 1 shared A. Orlova· 1 shared A. Ramspacher· 1 shared A. Strobl· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

F. Aberger

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

STAT3 restricts prostate cancer metastasis and antiandrogen resistance by controlling LKB1/CREB signaling pathway

J. Pencik, C. Philippe, M. Schlederer, M. Pecoraro, S. Grund-Groeschke, W. J. Li, A. Tracz, I. Heidegger, S. Lagger, K. Trachtova, M. Oberhuber, E. Heitzer, O. Osman, H. A. Neubauer, B. Wingelhofer, , C. McKinney

This study identifies STAT3's role in restricting prostate cancer metastasis and antiandrogen resistance by regulating the LKB1/CREB signaling pathway in mouse models and human patients.

bioRxiv · Aug 25, 2022 · PreprintCancer Biology

Casein kinase 1D encodes a novel drug target in Hedgehog-GLI driven cancers and tumor-initiating cells resistant to SMO inhibition

E. Peer, S. K. Aichberger, F. Vilotic, G. Wolfgang, T. Parigger, S. Grund-Groeschke, D. P. Elmer, F. Rathje, A. Ramspacher, M. Zaja, S. Michel, S. Hamm, F. Aberger

This study identifies CSNK1D as a novel therapeutic target in Hedgehog-GLI driven cancers, showing its inhibition reduces tumor-initiating cell growth in both SMO-sensitive and -resistant settings.

bioRxiv · Jun 17, 2021Cancer Biology

Oncogenic GLI1 and STAT1/3 activation drives immunosuppressive tryptophan/kynurenine metabolism via synergistic induction of IDO1 in skin cancer cells

D. P. Elmer, V. Strobl, G. Stockmaier, H.-H. Dang, M. Wiederstein, D. Licha, A. Strobl, C. Sternberg, S. Tesanovic, S. Grund-Groeschke, W. Gruber, F. Wolff, R. Moriggl, A. Risch, R. Reischl, , F. Aberger

This study identifies IDO1-kynurenine pathway activation as a novel mechanism by which HH-IL6 and GLI-STAT signaling promote immunosuppression in skin cancer, suggesting combination therapy targeting these pathways.

bioRxiv · May 4, 2020 · PreprintCancer Biology

Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunity

S. Grund-Groeschke, D. Ortner, A. Szenes-Nagy, N. Zaborsky, R. Weiss, D. Neureiter, M. Wipplinger, A. Risch, P. Hammerl, R. Greil, M. Sibilia, I. K. Gratz, P. Stoitzner, F. Aberger

This study investigates how Hedgehog signaling in skin cancer modulates immune cells and resistance to immunotherapy, identifying potential targets for combination treatments.

bioRxiv · Sep 15, 2019Cancer Biology